Italian LNP Cup

Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2

Retrieved on: 
Monday, October 16, 2023

BALTIMORE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology. The data, published on medRxiv, demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity. With clinical evidence that the c-srRNA platform is safe and can produce a T cell-mediated response, the Company is exploring its potential for the development of vaccines, cell therapies and immunotherapies for several indications.

Key Points: 
  • The data, published on medRxiv , demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity.
  • The results from this trial suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
  • This allows for the vaccine to be delivered intradermally, which is a method that’s been shown to induce strong T cell-mediated immunity.
  • Data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.

DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Key Points: 
  • CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
    The issuer is solely responsible for the content of this announcement.
  • The CV0501 study follows the start of a Phase 1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus variant.
  • The comprehensive approach to evaluate both an unmodified and a modified, second-generation vaccine candidate against COVID-19 is expected to identify the best-performing candidate for later-stage clinical development.
  • CV0501 is CureVacs first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK.

DGAP-News: CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Retrieved on: 
Friday, April 1, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Key Points: 
  • CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
    The issuer is solely responsible for the content of this announcement.
  • CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
    - Phase 1 dose-escalation study started at clinical sites in the U.S.
    TBINGEN, Germany/ BOSTON, USA - March 30, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.
  • CV2CoV is CureVac's first COVID-19 vaccine candidate based on the advanced second-generation mRNA backbone from the broad second-generation program, currently developed in collaboration with GSK.
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies.

Lega Nazionale Pallacanestro & ViewLift Announce Video Streaming Alliance

Retrieved on: 
Thursday, June 27, 2019

BOLOGNA, Italy and LONDON, June 27, 2019 /PRNewswire/ --Today,ViewLift, a leading global streaming technology platform, announces its alliance with Lega Nazionale Pallacanestro (LNP) to power the first European basketball league to launch on Amazon Fire TV, IOS TV and Roku Apps.

Key Points: 
  • BOLOGNA, Italy and LONDON, June 27, 2019 /PRNewswire/ --Today,ViewLift, a leading global streaming technology platform, announces its alliance with Lega Nazionale Pallacanestro (LNP) to power the first European basketball league to launch on Amazon Fire TV, IOS TV and Roku Apps.
  • "The agreement with ViewLift, one of the most important media companies for digital content distribution on dedicated platform, isa source of great pride for us at Lega Nazionale Pallacanestro," underlines Pietro Basciano, LNP President.
  • The ViewLift state-of-the-art streaming platform will now allow LNP to bring the Serie A2 (2nd National League) and Serie B (3rd) to a larger scale fan-base.
  • ViewLift operates a worldwide OTT platform that will transform the viewership experience for LNP fans through ubiquitous streaming over the leading over-the-top devices.